cagrisema cagrilintide semaglutide phase 3 obesity Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major Cagrilintide–Semaglutide in Adults with Overweight

2019;22:E4552

Most published findings originate from cell-based studies and animal models

In January 2025, the FDA quietly took down its draft Diversity Action Plan guidance from its website, and by May, Novo Nordisk had elected to remove its own gender-quota policy for US operations

Recently, to approach particular skin wound therapy, we and others reviewed the significance of its beneficial effect on muscle, tendon, ligament, and bone injuries (Gwyer et al., 2019

For another key nutrient in this space, see our guide on magnesium for anxiety and stress, which covers the GABA and parasympathetic pathways that complement what B12 does on the neurotransmitter side